Benefits of infusion pump technology in treatment of patients with acquired hemophilia A and hemophilia A with inhibitor a Polish pilot observational study

Introduction: The authors compared the efficacy, practicality and personnel preference of the infusion pump method against those of bolus administration of rFVIIa. Material and methods: Three patients with hemophilia A received recombinant factor VIIa infusion pump treatment. Their hemostasis and response to treatment was strictly monitored. Nursing personnel (n = 20) were surveyed on their preference and opinion regarding the infusion pump compared to bolus administration of recombinant factor VIIa. Results: The maintenance of hemostasis was satisfactory in the group of patients who were administered recombinant factor VIIa via infusion pump, and no dosage was missed or delayed. A large majority of the surveyed personnel (75%) evaluated the infusion pump as offering a more comfortable and easier administration method than 4-hourly boluses. Conclusions: Recombinant factor VIIa via infusion pump is more effective in maintaining hemostasis and is the preferred administration method among nursing personnel. Patients and personnel alike benefit from infusion pump administration of recombinant factor VIIa for hemophilia A.